Friday, January 28, 2022 – 06:52 WIB
–
The good news is that Daewoong Pharmaceutical has successfully entered the clinical trial stage for the treatment of diabetes. Illustration of a blood sugar measuring device. Photo: Pixabay
jpnn.com, JAKARTA – The good news is that Daewoong Pharmaceutical has successfully entered the clinical trial stage for the treatment of diabetes.
CEOs Jeon Seung-ho and Lee Changjae announced the results of Enavogliflozin monotherapy and metformin combination therapy, a new diabetes drug with an SGLT-2 inhibitory mechanism.
Enavogliflozin is a drug diabetes The first and new SGLT-2 inhibitor developed by Daewoong Pharmaceutical from Korea.
“It is hoped that this clinical success will lead to a time when we will be able to prescribe the best domestic diabetes drugs in the world.”
the class is for domestic patients,” said Jeon Seung-ho.
He hopes that Enavogliflozin will be able to reduce the discomfort of diabetic patients, while guaranteeing the company’s growth.
Principal investigator Professor Park Kyung-soo of Seoul National University Hospital, and researchers from 22 institutions participated in this phase 3 monotherapy clinical trial.
Professor Park Kyung-soo explained that the study involved 160 patients with type 2 diabetes.
They get treatment study in a multi-organ, randomized, double-blind, placebo-controlled, and therapeutic confirmation manner.
–
